Postdoctoral Fellow in Cancer Research

Sloan Kettering Memorial Cancer Center

Company overview

The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years.

 

In compliance with applicable State regulatory authorities, COVID-19 vaccination is mandatory for all MSK staff. Staff are considered fully vaccinated upon completion of a primary vaccination series for COVID-19 (i.e., one dose of a single dose vaccine or a final dose of a multi-dose vaccine series). Exceptions from the COVID-19 vaccine requirement are permitted for those who request and receive an approved medical or fully remote exemption.  Requests for medical exemption can take up to two weeks to review. Vaccination or an approved medical exemption is required to start work.

 

*Staff working at a MSK New Jersey location must be up to date with COVID-19 vaccination, which includes having completed the primary COVID-19 vaccination series and booster once eligible as mandated by New Jersey State. All New Jersey staff not yet eligible for a booster must receive a booster within 3 weeks of becoming eligible as a condition of continued employment at MSK.

 

Note: Individuals are eligible to receive a COVID-19 booster two months after completion of a primary vaccination series for COVID-19.  Because vaccine-induced immunity can wane over time, MSK continues to strongly urge all staff to get a COVID-19 booster as soon as they become eligible to maintain their protective immunity for a longer period.

Job details

The Emily Cheng laboratory at the Human Oncology & Pathogenesis Program is seeking highly motivated and successful individuals to study the molecular mechanisms of cell death and their implications in tumorigenesis, tumor-microenvironment interactions, targeted therapy, and immunotherapy (Science 330: 1390-1393; Cancer Cell 39: 1245-1261; Nature Cancer 3: 188-202; Molecular Cell 36: 487-499; Nature Cell Biology 8: 1348-1358; Nature Cell Biology 17: 1270-1281; Nature Communications 7: 13131;). The research projects are aimed at delineating aberrant survival/death signaling pathways in cancer, studying epigenetic regulation of cell death and epigenetic mechanisms of resistance to targeted therapy, interrogating the impact of different types of cell death (apoptosis, BAX/BAK-dependent immunogenic cell death, pyroptosis, necroptosis, ferroptosis, etc.) on tumor-immune crosstalk and immunotherapy, and identifying therapeutic strategies that trigger potent immunogenic cell death in cancer.

 

The ideal candidate should have:

  • Ph.D. degree
  • Strong background in cancer biology, immunology, and mouse models
  • Good publication record

If you have any questions about this job opportunity, please contact:

 

Emily Cheng, M.D., Ph.D.

Chenge1@mskcc.org

 

Salary: $55,439 – $100,940

Application Process
01
Step 1
Complete an Online Application
02
Step 2
Interview Process
03
Step 3
Provide References
04
Step 4
Extension of Job Offer
05
Step 5
Onboarding
06
Step 6
New Employee Orientation